{"title":"Best Sellers","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis collection brings together the best peptides Canada-shipped from our catalog — the research compounds most frequently sourced by Canadian laboratories, independent investigators, and research groups. For buyers looking to buy peptides Canada-wide, this collection represents what Canadian researchers actually order most often: bestselling compounds across metabolic, repair, mitochondrial, and regulatory peptide categories. Every compound here is supplied at ≥99% HPLC purity, MS-verified identity, and accompanied by a batch-specific certificate of analysis.\u003c\/span\u003e\u003c\/p\u003e","products":[{"product_id":"buy-retatrutide-canada","title":"GLP-3 (Retatrutide)","description":"\u003ch2\u003eBuy Retatrutide in Canada — Triple-Agonist Research Peptide\u003c\/h2\u003e\n\u003cp\u003eBuy Retatrutide in Canada as a research-grade triple receptor agonist for metabolic, glycemic, and adiposity research designs. Retatrutide (LY3437943) is an investigational triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly, with Phase 2 clinical data published in 2023 showing dose-dependent body weight reductions and HbA1c improvements. The compound combines balanced agonist activity across all three target receptors with structural modifications — Aib substitutions and C20 fatty diacid acylation — that extend half-life through albumin binding. Each vial supplied by Emerald Peptides ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.\u003c\/p\u003e\n\u003ch2\u003eProduct Details\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C221H342N46O68 \/ 4728.8 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 2381089-83-2\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eWhat Makes Retatrutide a Unique Compound\u003c\/h2\u003e\n\u003cp\u003eRetatrutide is the only compound in advanced clinical investigation that simultaneously activates the GLP-1, GIP, and glucagon receptors. Earlier incretin peptides target one or two; the addition of glucagon-receptor agonism reintroduces a hepatic and energy-expenditure dimension that mono- and dual-agonists cannot address.\u003c\/p\u003e\n\u003cp\u003eDeveloped at Eli Lilly and disclosed in 2022 under the code LY3437943, retatrutide carries Aib substitutions for DPP-4 resistance and a C20 fatty diacid for albumin binding and extended circulation. Phase 2 trial data published in 2023 in major peer-reviewed medical journals reported dose-dependent changes in body weight and HbA1c, making it a reference tool compound for researchers comparing the contributions of each receptor pathway.\u003c\/p\u003e\n\u003ch2\u003eKey Benefits\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eGlycemic Regulation —\u003c\/b\u003e Phase 2 trial data published in 2023 reported dose-dependent reductions in HbA1c in study populations with type 2 diabetes, supporting investigation into the contribution of triple-receptor activation to glucose handling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAdiposity \u0026amp; Body Composition —\u003c\/b\u003e Animal and clinical trial datasets describe substantial reductions in fat mass over 24- and 48-week protocols, with investigators attributing the magnitude to combined incretin and glucagon-receptor effects on intake and expenditure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eHepatic Lipid Metabolism —\u003c\/b\u003e Researchers studying NAFLD and MASH models have examined retatrutide's effect on hepatic triglyceride content, where glucagon-receptor agonism is hypothesized to drive intrahepatic lipid mobilization beyond what GLP-1 alone produces.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnergy Expenditure —\u003c\/b\u003e Preclinical work in rodent models has reported elevations in resting energy expenditure attributed to the glucagon receptor component, distinguishing retatrutide from GLP-1 monotherapy in mechanistic dissection studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCardiometabolic Markers —\u003c\/b\u003e Secondary endpoints in published trials have included blood pressure, lipid panel, and inflammatory markers, giving researchers additional data points for modeling broader cardiometabolic effects of triple agonism.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eRelated Peptides\u003c\/h2\u003e\n\u003cp\u003eResearchers working with retatrutide often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-tesamorelin-canada\"\u003eTesamorelin\u003c\/a\u003e\u003c\/b\u003e — GH-axis analog studied in visceral adiposity and lipid metabolism research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-mots-c-canada\"\u003eMOTS-c\u003c\/a\u003e\u003c\/b\u003e — Mitochondria-derived peptide investigated for insulin sensitivity and exercise-mimetic activity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/nad-plus\"\u003eNAD+\u003c\/a\u003e\u003c\/b\u003e — Mitochondrial cofactor studied alongside metabolic peptides in cardiometabolic and longevity research designs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eHow is retatrutide different from tirzepatide or semaglutide?\u003c\/h3\u003e\n\u003cp\u003eSemaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1\/GIP agonist. Retatrutide adds a third arm — glucagon receptor agonism — which preclinical and Phase 2 data suggest contributes additional hepatic lipid mobilization and energy expenditure effects not observed with mono- or dual-agonist compounds.\u003c\/p\u003e\n\u003ch3\u003eWhat is the evidence base for retatrutide?\u003c\/h3\u003e\n\u003cp\u003ePhase 2 trials in obesity and type 2 diabetes have been completed and published in major peer-reviewed medical journals, including data on body weight, glycemic markers, and tolerability. Phase 3 development is ongoing under Eli Lilly's TRIUMPH program.\u003c\/p\u003e\n\u003ch3\u003eIs retatrutide naturally occurring?\u003c\/h3\u003e\n\u003cp\u003eNo. Retatrutide is a synthetic 39-amino-acid peptide engineered with non-natural Aib substitutions for protease resistance and a C20 fatty diacid acylation for extended circulation. It does not exist in nature.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003ci\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/i\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":45745388290185,"sku":null,"price":89.99,"currency_code":"CAD","in_stock":true},{"title":"6 x 10mg","offer_id":45745388322953,"sku":null,"price":489.99,"currency_code":"CAD","in_stock":true},{"title":"10 x 10mg (one box)","offer_id":45745388355721,"sku":null,"price":739.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/retatrutide-ly3437943-10mg-research-peptide_standardized.png?v=1778371040"},{"product_id":"buy-bpc-157","title":"BPC-157","description":"\u003ch2\u003e\u003cb\u003eBuy BPC-157 — Gastric-Derived Pentadecapeptide\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003eBuy BPC-157 from Emerald Peptides as a research-grade pentadecapeptide for tissue repair, cytoprotection, and gastrointestinal research designs. BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of body protective compound (BPC), originally isolated from human gastric juice. With more than 100 published animal studies covering gastrointestinal injury, musculoskeletal repair, vascular research, and neural protection models, BPC-157 has one of the broadest preclinical evidence bases in the recovery research peptide category. Each vial ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e [CONFIRM — common SKU sizes: 5 mg \/ 10 mg]\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C₆₂H₉₈N₁₆O₂₂ \/ 1419.55 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 137525-51-0\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes BPC-157 a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eBPC-157 was characterized by Croatian researchers in the early 1990s as a stable fragment of body protective compound, a larger protein found in gastric juice. What set it apart immediately was its stability in acidic gastric environments and its activity without a carrier protein — properties that made it accessible for a wide range of preclinical models.\u003c\/p\u003e\n\u003cp\u003eThe peptide's broad-tissue activity is unusual. Published animal studies report effects on smooth muscle, tendon, ligament, bone, gut mucosa, and vascular endothelium, with mechanistic work pointing to nitric-oxide pathway modulation and pro-angiogenic VEGFR2 signaling. This combination makes BPC-157 a frequent reference compound in repair and cytoprotection research, including studies modeling NSAID-induced gastric injury where conventional models have struggled to find responsive tools.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eGastrointestinal Cytoprotection —\u003c\/b\u003e Animal studies report protective effects against NSAID-induced and stress-induced gastric lesions, with researchers attributing the activity to nitric oxide pathway modulation and mucosal repair signaling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eTendon \u0026amp; Ligament Repair —\u003c\/b\u003e Published rodent models, including transected Achilles tendon and medial collateral ligament studies, have reported accelerated reorganization of collagen and fibroblast migration in BPC-157-treated groups versus controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAngiogenesis \u0026amp; Vascular Remodeling —\u003c\/b\u003e Preclinical work has documented upregulation of VEGFR2 expression and improved capillary density in injury models, supporting investigation into BPC-157's role in tissue vascularization research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNeuroprotection —\u003c\/b\u003e Animal models of traumatic brain injury, peripheral nerve transection, and ischemic insult have reported reduced lesion progression and improved functional recovery in BPC-157 cohorts, generating ongoing interest in CNS repair research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAnti-Inflammatory Modulation —\u003c\/b\u003e Studies have measured reductions in pro-inflammatory cytokine expression and improved outcomes in colitis and arthritis models, framing BPC-157 as a candidate for investigation into systemic inflammatory responses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with BPC-157 often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/tb500-peptides\" title=\"View TB-500 Product Page\"\u003eTB-500\u003c\/a\u003e\u003c\/b\u003e — Thymosin β4 fragment studied for cellular migration and angiogenesis; the most common pairing in published soft-tissue repair research and the basis of our Wolverine Stack (see below).\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/ghk-cu\" title=\"View GHK-Cu Product Page\"\u003eGHK-Cu\u003c\/a\u003e\u003c\/b\u003e — Copper tripeptide investigated for ECM remodeling and wound repair; complements BPC-157's cytoprotective profile with a copper-mediated gene-expression angle, and pairs with both compounds in our \u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/glow-peptide-canada\" title=\"View Glow Stack Product Page\"\u003e\u003cstrong\u003eGlow Stack.\u003c\/strong\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/bpc-157-tb-500-stack\" title=\"View Wolverine Stack Product Page\"\u003eWolverine Stack\u003c\/a\u003e\u003c\/b\u003e — Combined BPC-157 + TB-500 research blend for groups studying repair pathways in parallel.\u003cstrong\u003e\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-retatrutide-canada\" title=\"View Retatrutide Product Page\"\u003eRetatrutide (GLP-3)\u003c\/a\u003e \u003c\/strong\u003e\u003cmeta charset=\"utf-8\"\u003e — BPC-157's activity in NAFLD and MASH models pairs with hepatic-lipid research using Retatrutide.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eHow is BPC-157 different from TB-500?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eBoth are studied in tissue repair contexts but engage different pathways. BPC-157 is a 15-amino-acid pentadecapeptide derived from gastric BPC, with mechanistic work focused on nitric oxide signaling and VEGFR2-mediated angiogenesis. TB-500 is a synthetic fragment of thymosin β4 and is studied primarily for actin-binding-driven cell migration. Many research designs use them together to model complementary repair pathways.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs BPC-157 naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePartially. The 15-amino-acid sequence corresponds to a region of body protective compound, a protein identified in human gastric juice. The synthetic peptide sold for research is the isolated pentadecapeptide fragment — it does not occur as a free peptide in nature, but its sequence is drawn from a naturally occurring parent protein.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhat is the evidence base for BPC-157?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe published preclinical literature spans more than three decades and over 100 animal studies across gastrointestinal, musculoskeletal, vascular, and neural models. A 2022 pharmacokinetic study in Frontiers in Pharmacology characterized distribution and metabolism in rats and dogs. Human clinical data remain limited, with most evidence drawn from rodent and other animal models.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003cem\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":45745392615561,"sku":null,"price":82.99,"currency_code":"CAD","in_stock":true},{"title":"6 x 10mg","offer_id":45745392648329,"sku":null,"price":439.99,"currency_code":"CAD","in_stock":true},{"title":"10 x 10mg (one box)","offer_id":45745392681097,"sku":null,"price":639.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/bpc-157-10mg-peptide-canada_standardized_7e837585-deaf-40ab-bf7d-f053e8e998f2.png?v=1778370991"},{"product_id":"tb500-peptides","title":"TB-500","description":"\u003ch2\u003e\u003cb\u003eBuy TB500 Peptides — Synthetic Thymosin β-4\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTB500 peptides from Emerald Peptides supply research-grade synthetic thymosin β-4 for cellular migration, angiogenesis, and cardiac repair research designs. TB-500 is a synthetic version of the full 43-amino-acid thymosin β-4, endogenous to most mammalian cell types and one of the most extensively studied actin-binding peptides in molecular biology. Originally characterized by Allan Goldstein and colleagues in 1981, TB-500 has become a standard reference compound across cardiac repair, wound healing, and dermal regeneration research. Each TB500 vial ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C₂₁₂H₃₅₀N₅₆O₇₈S \/ 4963.44 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 77591-33-4\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes TB-500 a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eThymosin β-4 was first isolated from calf thymic tissue in 1981 by Allan Goldstein and colleagues, with subsequent decades of research expanding its role beyond the immune system to include broad tissue-repair and cytoskeletal-regulation functions. The synthetic 43-amino-acid form, popularized as TB-500 in research and veterinary contexts, became a standard tool for groups studying actin dynamics in vivo.\u003c\/p\u003e\n\u003cp\u003eWhat distinguishes TB-500 from other repair-focused peptides is its mechanistic specificity. By acting as the principal G-actin sequestering peptide, it provides researchers with a defined molecular handle on cytoskeletal organization — a starting point for downstream investigation of cell migration, angiogenic transcriptional programs, and tissue regeneration. Its activity across endothelial, fibroblast, keratinocyte, and cardiomyocyte systems makes it one of the few peptide tools relevant across multiple parallel research domains.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eCellular Migration \u0026amp; Wound Repair —\u003c\/b\u003e Published in vitro and rodent studies report accelerated keratinocyte migration, fibroblast recruitment, and re-epithelialization kinetics in TB-500-treated wound models, with mechanistic work linking effects to G-actin sequestration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAngiogenesis \u0026amp; Vascular Remodeling —\u003c\/b\u003e Animal models have documented increased capillary density and endothelial cell organization in dermal and cardiac tissue, supporting investigation into TB-500's role in vascularization research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCardiac Tissue Models —\u003c\/b\u003e Preclinical studies in murine ischemia-reperfusion models have reported reduced infarct size and improved cardiomyocyte survival, generating sustained interest in TB-500 as a tool peptide for cardiac repair research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSkeletal Muscle \u0026amp; Soft Tissue Repair —\u003c\/b\u003e Published rodent injury models, including muscle crush and tendon laceration designs, describe accelerated recovery markers and improved tissue organization in treated cohorts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAnti-Inflammatory Modulation —\u003c\/b\u003e Cell-based and animal studies have measured reductions in inflammatory cytokine expression and modulation of NF-κB signaling, framing TB-500 as a candidate for investigation into inflammation-coupled tissue repair.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with TB-500 often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-bpc-157\" title=\"View BPC-157 Product Page\"\u003eBPC-157\u003c\/a\u003e\u003c\/b\u003e — Gastric pentadecapeptide studied for nitric-oxide-mediated cytoprotection and VEGFR2-driven angiogenesis; the most common pairing in published soft-tissue repair research, formalized in our Wolvering Stack (see below).\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/ghk-cu\" title=\"View GHK-Cu Product Page\"\u003eGHK-Cu\u003c\/a\u003e\u003c\/b\u003e — Copper tripeptide investigated for ECM remodeling and gene-expression modulation; complements TB-500's cytoskeletal mechanism with a copper-mediated repair angle, and pairs with both compounds in our \u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/glow-peptide-canada\" title=\"View Glow Stack Product Page\"\u003e\u003cstrong\u003eGlow Stack.\u003c\/strong\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/bpc-157-tb-500-stack\" title=\"View Wolverine Stack Product Page\"\u003eWolverine Stack\u003c\/a\u003e\u003c\/b\u003e — Combined BPC-157 + TB-500 research blend for groups studying repair pathways in parallel.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-retatrutide-canada\" title=\"View Retatrutide Product Page\"\u003e\u003cstrong\u003eRetatrutide (GLP-3)\u003c\/strong\u003e\u003c\/a\u003e \u003cmeta charset=\"utf-8\"\u003e — TB-500's cardiac-research literature complements cardiometabolic designs incorporating Retatrutide.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eIs TB-500 the same as thymosin β-4?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eFunctionally, yes — TB-500 sold as a research peptide is a synthetic version of the full 43-amino-acid thymosin β-4 sequence. The TB-500 designation originated in veterinary and research contexts, while \"thymosin β-4\" is the original biochemical name. Note that some suppliers sell a much shorter 7-amino-acid fragment (Ac-LKKTETQ) under the TB-500 name; ours is the full 43-aa peptide.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is TB-500 different from BPC-157?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eBoth are studied in tissue repair contexts but engage different mechanisms. TB-500 acts on the actin cytoskeleton via G-actin sequestration, regulating cell migration and angiogenesis. BPC-157 is a 15-amino-acid pentadecapeptide derived from gastric BPC, with mechanistic work focused on nitric oxide signaling and VEGFR2-mediated vascular remodeling. Many research designs use them together to model complementary repair pathways.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhat is the evidence base for TB-500?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe thymosin β-4 literature spans more than four decades, with hundreds of cell-based and animal studies across wound healing, cardiac repair, neural regeneration, and inflammation models. Mechanistic studies have characterized actin-binding kinetics and downstream signaling. Clinical-stage human data remain limited; the bulk of evidence sits in rodent, large-animal, and cell-system research.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003cem\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":45745396842633,"sku":null,"price":89.99,"currency_code":"CAD","in_stock":true},{"title":"6x10mg","offer_id":45745396875401,"sku":null,"price":479.99,"currency_code":"CAD","in_stock":true},{"title":"10x10mg (one box)","offer_id":45745396908169,"sku":null,"price":649.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/tb-500-10mg-peptide-canada_standardized.png?v=1778370915"},{"product_id":"bpc-157-tb-500-stack","title":"Wolverine Stack (BPC-157 + TB-500)","description":"\u003ch2\u003e\u003cb\u003eBPC-157 + TB-500 Stack — The Wolverine Stack Blend\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe Wolverine Stack combines BPC-157 and TB-500 into a single matched-batch research kit for parallel-pathway tissue repair and recovery research designs. This BPC-157 TB-500 stack is built around mechanistic complementarity — BPC-157 engages nitric oxide signaling and VEGFR2-mediated angiogenesis, while TB-500 engages actin cytoskeleton regulation through G-actin sequestration. The two pathways don't overlap, which means research designs can probe both vascular and cytoskeletal mechanisms simultaneously without confounding mechanism-specific effects. Both compounds in the stack ship at ≥99% HPLC purity with mass-spec-verified identity, separate batch-specific certificates of analysis, and fast domestic Canadian shipping.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Two lyophilized peptides, supplied as a kit\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per kit:\u003c\/b\u003e 10 mg BPC-157 + 10 mg TB-500 (each filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified, both components)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified per COA (both components)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eComponents:\u003c\/b\u003e See individual product pages for full sequence, formula, MW, and CAS data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes the Wolverine Stack a Unique Combination\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eThe BPC-157 TB-500 stack reflects what is now the most common pairing in published soft-tissue repair research with these two peptides. The rationale is mechanistic non-overlap: rather than two compounds acting through the same pathway with redundant effects, BPC-157 and TB-500 engage distinct targets — the former operating through nitric-oxide-pathway and VEGFR2 modulation, the latter through actin-cytoskeleton regulation. Research designs that incorporate both compounds can therefore probe parallel repair pathways in the same model system without confounding mechanism-specific effects.\u003c\/p\u003e\n\u003cp\u003eThe combination also reflects the breadth of the underlying literature. BPC-157 has been characterized in over 100 published animal studies spanning gastrointestinal, musculoskeletal, vascular, and neural injury models. The thymosin β-4 literature spans more than four decades and covers wound healing, cardiac repair, neural regeneration, and inflammation. The Wolverine Stack gives Canadian research groups a single supply point for both reference compounds, with batch-specific certificates of analysis confirming ≥99% HPLC purity for each constituent.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eParallel Repair Pathway Investigation —\u003c\/b\u003e The combination allows research designs to address nitric-oxide-pathway and actin-cytoskeleton mechanisms simultaneously, with each peptide serving as a tool for its respective pathway in the same model system.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSoft Tissue \u0026amp; Tendon Models —\u003c\/b\u003e Published rodent studies of Achilles tendon transection, medial collateral ligament injury, and muscle crush have characterized BPC-157 and TB-500 effects independently; combined research designs build on both literatures.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAngiogenesis \u0026amp; Vascular Remodeling —\u003c\/b\u003e Both peptides have documented pro-angiogenic activity — BPC-157 via VEGFR2 upregulation, TB-500 via endothelial cell migration and capillary network organization — making the stack a focused tool for vascular research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCardiac Repair Research —\u003c\/b\u003e Murine ischemia-reperfusion models have separately reported reduced infarct size with TB-500 and improved vascular outcomes with BPC-157, with combined-administration designs appearing in more recent published preclinical work.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eInflammatory Modulation —\u003c\/b\u003e Both compounds have measured effects on cytokine expression and NF-κB signaling in published models, supporting research designs that address tissue repair coupled with inflammatory-pathway endpoints.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with the Wolverine Stack often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-bpc-157\" title=\"View BPC-157 Product Page\"\u003eBPC-157\u003c\/a\u003e\u003c\/b\u003e — Available as a single-compound vial for research designs requiring BPC-157 alone or at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/tb500-peptides\" title=\"View TB-500 Product Page\"\u003eTB-500\u003c\/a\u003e\u003c\/b\u003e — Available as a single-compound vial for research designs requiring TB-500 alone or at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/glow-peptide-canada\" title=\"View Glow Stack Product Page\"\u003eGlow Stack\u003c\/a\u003e\u003c\/b\u003e — Adds GHK-Cu to the BPC-157 + TB-500 backbone for research designs extending repair endpoints into ECM remodeling and skin biology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhere can researchers buy the BPC-157 TB-500 stack in Canada with verified purity?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eOur Wolverine Stack ships to Canadian research labs and independent investigators with two batch-specific certificates of analysis — one per component — confirming ≥99% HPLC purity and mass-spec identity verification for both BPC-157 and TB-500. Each vial is filled to approximately 104% of the labeled 10 mg as a quality margin for residual losses during reconstitution work, and orders dispatch from within Canada to avoid border-related cold-chain interruptions.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is the Wolverine Stack different from buying BPC-157 and TB-500 separately?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eFunctionally, the contents are identical to single-compound vials of each peptide. The Wolverine Stack format is a packaging convenience for research designs that always use the two compounds together — kit shipping reduces logistics overhead, and matched batch documentation is provided. For research designs that require one compound at a different ratio than the other, or that don't always use both, sourcing each compound individually may be more appropriate.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhy are BPC-157 and TB-500 so commonly studied together?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe two peptides act through entirely different molecular mechanisms, which makes their combination useful for parallel pathway investigation rather than redundant pathway coverage. BPC-157 modulates nitric oxide signaling and upregulates VEGFR2-mediated angiogenesis. TB-500 regulates the actin cytoskeleton through G-actin sequestration. In published animal studies of soft-tissue injury, the two compounds appear together more frequently than any other peptide pairing in the repair-research literature.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eAre both peptides naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePartially, in different ways. BPC-157's 15-amino-acid sequence corresponds to a region of body protective compound, a protein identified in human gastric juice; the synthetic peptide is the isolated fragment. TB-500 is the synthetic full-length sequence of thymosin β-4, an actin-binding peptide endogenous to most mammalian cell types and originally isolated from calf thymic tissue.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️\u003cem\u003e For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg\/10mg","offer_id":46054364414089,"sku":null,"price":154.99,"currency_code":"CAD","in_stock":true},{"title":"6 x 10mg\/10mg","offer_id":46134481715337,"sku":null,"price":879.99,"currency_code":"CAD","in_stock":false},{"title":"10 x 10mg\/10mg (one box)","offer_id":46054364446857,"sku":null,"price":1149.99,"currency_code":"CAD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/bpc-157-tb-500-wolverine-stack-peptide-canada_standardized_45005065-9a0a-4d37-aaf6-d266514f1b1d.png?v=1778371509"},{"product_id":"glow-peptide-canada","title":"Glow Stack (BPC-157 + TB-500 + GHK-Cu)","description":"\u003ch2\u003e\n\u003cmeta charset=\"utf-8\"\u003eBPC-157 + TB-500 + GHK-Cu Stack — The Glow Stack for Multi-Pathway Research\u003c\/h2\u003e\n\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003eThe Glow Stack combines BPC-157, TB-500, and GHK-Cu into a single matched-batch research kit for multi-pathway dermal repair, ECM remodeling, and tissue-level research designs. Each compound in the BPC-157 TB-500 GHK-Cu stack engages a distinct mechanism — BPC-157 through nitric oxide pathway and VEGFR2-mediated angiogenesis, TB-500 through G-actin sequestration and cellular migration regulation, and GHK-Cu through copper-mediated ECM remodeling and gene expression modulation. The mechanism non-overlap gives research designs three complementary tools in matched documentation. Each component ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificates of analysis, and fast domestic Canadian shipping.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Three lyophilized compounds, supplied as a kit\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per kit:\u003c\/b\u003e 10 mg BPC-157 + 10 mg TB-500 + 50 mg GHK-Cu (each filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified, all components)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified per COA (all components)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eComponents:\u003c\/b\u003e See individual product pages for full sequence, formula, MW, and CAS data\u003cb\u003e\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes the Glow Stack a Unique Combination\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eThe Glow Stack builds on the BPC-157 + TB-500 repair backbone — already the most frequent two-peptide pairing in published soft-tissue research — and adds GHK-Cu to extend the design into ECM remodeling, gene-expression modulation, and skin biology. The rationale is mechanistic stratification: each compound operates through a distinct molecular pathway, so research designs incorporating the full stack can probe parallel mechanisms in the same model system without confounding overlap.\u003c\/p\u003e\n\u003cp\u003eThe combination also reflects the breadth of supporting literature. BPC-157 has over 100 published animal studies across repair domains. The thymosin β-4 literature spans four decades. GHK-Cu's published research arc reaches back to its 1973 isolation from human plasma by Loren Pickart, with subsequent genomic profiling identifying expression changes across roughly 4,000 human genes. The Glow Stack gives Canadian research groups a single supply point for all three reference compounds, with batch-specific certificates of analysis confirming ≥99% HPLC purity for each constituent.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eMulti-Pathway Skin \u0026amp; ECM Research —\u003c\/b\u003e The stack allows research designs to address nitric-oxide-pathway, actin-cytoskeleton, and copper-mediated ECM-remodeling mechanisms simultaneously, giving each compound a defined role in the same model system.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCollagen \u0026amp; Glycosaminoglycan Synthesis —\u003c\/b\u003e GHK-Cu has documented effects on dermal fibroblast collagen, decorin, and glycosaminoglycan production. Combined with BPC-157 and TB-500's separate repair-pathway activity, the stack covers structural ECM endpoints alongside vascular and cytoskeletal mechanisms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eHair Follicle Research —\u003c\/b\u003e GHK-Cu has measured effects on hair follicle morphology and anagen-phase signaling in animal and ex vivo models. Stacked with BPC-157 and TB-500's vascular and cytoskeletal contributions, the combination supports hair-biology research with multiple parallel mechanisms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eWound Repair \u0026amp; Re-Epithelialization —\u003c\/b\u003e All three compounds have published activity in rodent wound models — BPC-157 via cytoprotection and angiogenesis, TB-500 via keratinocyte and fibroblast migration, GHK-Cu via fibroblast recruitment and pro-angiogenic gene expression. Combined research designs build on three independent literatures.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eGene Expression \u0026amp; Transcriptomic Research —\u003c\/b\u003e GHK-Cu's documented activity across thousands of human genes makes the Glow Stack uniquely suited to research designs combining functional repair endpoints with transcriptomic analysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with the Glow Stack often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-bpc-157\" title=\"View BPC-157 Product Page\"\u003eBPC-157\u003c\/a\u003e\u003c\/b\u003e — Available as a single-compound vial for research designs requiring BPC-157 alone or at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/tb500-peptides\" title=\"View TB-500 Product Page\"\u003eTB-500\u003c\/a\u003e\u003c\/b\u003e — Available as a single-compound vial for research designs requiring TB-500 alone or at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/ghk-cu\" title=\"View GHK-Cu Product Page\"\u003eGHK-Cu\u003c\/a\u003e\u003c\/b\u003e — Available as a single-compound vial for research designs requiring GHK-Cu alone or at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/bpc-157-tb-500-stack\" title=\"View Wolverine Stack Product Page\"\u003eWolverine Stack\u003c\/a\u003e\u003c\/b\u003e — The two-compound BPC-157 + TB-500 backbone, for research designs that don't extend into ECM-remodeling and skin-biology endpoints.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhat makes this kit a glow peptide Canada researchers source for skin and ECM work?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThree reasons. First, the published preclinical literature for the constituent compounds — BPC-157, TB-500, and GHK-Cu — covers skin biology, ECM remodeling, hair follicle research, and wound repair across decades of work. Second, the mechanistic stratification across nitric-oxide, cytoskeletal, and copper-mediated ECM pathways gives research designs clean tool separation. Third, sourcing all three compounds as a matched-batch kit shipped from within Canada simplifies documentation and avoids cold-chain interruptions at the border.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is the Glow Stack different from the Wolverine Stack?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe Wolverine Stack is the two-compound BPC-157 + TB-500 repair backbone, focused on soft-tissue and angiogenesis research. The Glow Stack adds GHK-Cu to that backbone, extending the design into ECM remodeling, broad gene-expression modulation, and skin-biology research. Research groups studying tendon, ligament, or muscle repair without dermal endpoints typically work with the Wolverine Stack; groups whose designs include skin, hair, or ECM-remodeling research add GHK-Cu and use the Glow Stack.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhy are these three compounds frequently studied together in skin research?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eEach operates through a distinct mechanism with documented activity in dermal and connective-tissue models. BPC-157 contributes cytoprotection and VEGFR2-mediated angiogenesis. TB-500 contributes cellular migration and capillary network formation through G-actin sequestration. GHK-Cu contributes ECM-remodeling, collagen and glycosaminoglycan synthesis, and broad gene-expression modulation through copper-mediated signaling. Combined research designs cover three parallel mechanisms in a single model.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eAre the three compounds naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eIn varying degrees. BPC-157's 15-amino-acid sequence corresponds to a region of body protective compound found in human gastric juice; the synthetic peptide is the isolated fragment. TB-500 is the synthetic full-length sequence of thymosin β-4, endogenous to most mammalian cell types. GHK-Cu is fully endogenous, present in human plasma, saliva, and urine, and released at sites of tissue injury through breakdown of SPARC and type I collagen. The synthetic preparations are sequence-identical to their endogenous forms.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg\/10mg\/50mg (one vial)","offer_id":46210700640393,"sku":null,"price":164.99,"currency_code":"CAD","in_stock":false},{"title":"6 x 10mg\/10mg\/50mg","offer_id":46210700673161,"sku":null,"price":889.99,"currency_code":"CAD","in_stock":false},{"title":"10 x 10mg\/10mg\/50mg (one box)","offer_id":46210700705929,"sku":null,"price":1299.99,"currency_code":"CAD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/bpc-157-tb-500-ghk-cu-glow-stack-peptide-canada_standardized_2f465125-607f-4157-baaf-dafbcb43a096.png?v=1778371780"},{"product_id":"mots-c-ss31-nad-stack","title":"Mito Stack (MOTS-c + SS-31 + NAD+)","description":"\u003ch2\u003e\u003cb\u003eMOTS-c + SS-31 + NAD+ Stack — The Mito Stack Blend\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe Mito Stack combines MOTS-c, SS-31, and NAD+ into a single matched-batch research kit for three-layer mitochondrial bioenergetics research designs. This MOTS-c SS-31 NAD+ stack addresses mitochondrial biology at three distinct levels — MOTS-c provides signaling-layer intervention through AMPK activation, SS-31 provides structural-layer intervention through cardiolipin binding and cristae stabilization, and NAD+ provides biochemical-layer intervention as the cofactor underlying sirtuin signaling and electron transport chain operation. All three compounds in the stack ship at ≥99% HPLC purity with mass-spec-verified identity, separate batch-specific certificates of analysis, and fast domestic Canadian shipping.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Three lyophilized compounds, supplied as a kit\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per kit:\u003c\/b\u003e 10 mg MOTS-c + 10 mg SS-31 + 600 mg NAD+ (each filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified, all components)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified per COA (all components)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light; long-term NAD+ storage at −20 °C\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eComponents:\u003c\/b\u003e See individual product pages for full sequence, formula, MW, and CAS data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes the Mito Stack a Unique Combination\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eThe MOTS-c SS-31 NAD+ stack reflects a deliberate stratification across the three principal layers of mitochondrial biology that researchers commonly investigate. MOTS-c addresses the signaling layer — communicating bioenergetic status from mitochondria to the nucleus and activating AMPK as a master energy-sensing kinase. SS-31 addresses the structural layer — binding cardiolipin on the inner mitochondrial membrane and stabilizing cristae morphology in compromised mitochondria. NAD+ addresses the biochemical layer — cycling between oxidized and reduced forms in redox reactions and serving as a consumed substrate for sirtuins, PARPs, and CD38.\u003c\/p\u003e\n\u003cp\u003eThis three-layer separation gives research groups clean mechanistic resolution. Rather than three compounds with overlapping modes of action, each operates at a distinct level of mitochondrial biology, allowing experimental designs to probe signaling, structural, and cofactor contributions in the same model system. The combination matches the modern mitochondrial-research literature, where studies frequently address all three layers simultaneously to characterize bioenergetic phenotypes in aging, metabolic, and cardiac models. As a longevity peptide stack Canada-shipped from a single supply point with matched batch documentation, the Mito Stack simplifies the documentation chain for laboratories operating under quality-control protocols.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eThree-Layer Mitochondrial Investigation —\u003c\/b\u003e The combination allows research designs to address signaling (MOTS-c \/ AMPK), structural (SS-31 \/ cardiolipin), and biochemical (NAD+ \/ redox and sirtuin) mechanisms simultaneously, with each compound serving a distinct role in the same model system.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAging \u0026amp; Longevity Research —\u003c\/b\u003e All three compounds connect to age-associated mitochondrial decline. MOTS-c plasma levels decline with age in published human and animal data. SS-31 has been studied in aged-rodent skeletal muscle and cardiac models. NAD+ tissue levels decline progressively with age. Combined research designs build on three independent literatures within longevity research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCardiac Bioenergetics —\u003c\/b\u003e Rodent ischemia-reperfusion models have separately characterized SS-31's effects on infarct size and mitochondrial respiration. NAD+ has been examined in heart failure and cardiometabolic models. MOTS-c has been studied for metabolic effects relevant to cardiac substrate handling. The stack supports research designs combining all three.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eInsulin Sensitivity \u0026amp; Metabolic Models —\u003c\/b\u003e MOTS-c activates AMPK to improve skeletal muscle glucose uptake. SS-31 has been characterized in type 2 diabetes models for effects on oxidative stress and ER stress. NAD+ has documented effects in rodent obesity and NAFLD models. The combination addresses metabolic dysfunction from three angles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eReactive Oxygen Species \u0026amp; Redox Biology —\u003c\/b\u003e SS-31 reduces mitochondrial ROS production via cardiolipin binding. NAD+ governs cellular redox state through NAD+\/NADH cycling. MOTS-c has been characterized for effects on antioxidant pathways through AMPK-mediated transcription. Combined research designs cover redox biology across structural and biochemical layers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with the Mito Stack often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-mots-c-canada\" title=\"View MOTS-c Product Page\"\u003eMOTS-c\u003c\/a\u003e\u003c\/b\u003e — Available as a single-compound vial for research designs requiring MOTS-c alone or at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-ss-31\" title=\"View SS-31 Product Page\"\u003eSS-31\u003c\/a\u003e\u003c\/b\u003e — Available as a single-compound vial for research designs requiring SS-31 alone or at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/nad-plus\" title=\"View NAD+ Product Page\"\u003eNAD+\u003c\/a\u003e\u003c\/b\u003e — Available as a single-compound vial for research designs requiring NAD+ alone or at non-stack ratios.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhere can researchers buy the MOTS-c SS-31 NAD+ stack in Canada with verified purity?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eOur Mito Stack ships to Canadian research labs and independent investigators with three batch-specific certificates of analysis — one per component — confirming ≥99% HPLC purity and mass-spec identity verification for MOTS-c, SS-31, and NAD+. Each vial is filled to approximately 104% of label as a quality margin for residual losses during reconstitution work, and orders dispatch from within Canada to avoid border-related cold-chain interruptions.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow are MOTS-c, SS-31, and NAD+ different from each other mechanistically?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eMOTS-c is a 16-amino-acid mitochondria-derived peptide that activates AMPK and acts as a signaling molecule between mitochondria and the nucleus — a regulatory mechanism. SS-31 is a synthetic tetrapeptide that binds cardiolipin on the inner mitochondrial membrane to stabilize cristae structure and reduce ROS production — a structural mechanism. NAD+ is a pyridine dinucleotide coenzyme that participates in redox cycling and serves as a consumed substrate for sirtuins, PARPs, and CD38 — a biochemical mechanism. The three compounds operate at different levels of mitochondrial biology.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhy combine these three compounds in a single research kit?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe combination matches how mitochondrial-research designs are typically structured. Studies of mitochondrial dysfunction in aging, cardiac disease, metabolic syndrome, and neurodegeneration often address signaling, structural, and biochemical layers simultaneously — because dysfunction at one layer typically propagates to the others. A single kit gives research groups all three reference compounds with matched batch documentation, simplifying experimental designs that probe parallel mechanisms.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs NAD+ a peptide?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eNo. NAD+ is a pyridine dinucleotide coenzyme — two nucleotides linked through their phosphate groups, not assembled from amino acids. It is included in the Mito Stack and catalogued alongside research peptides because of its central role in mitochondrial bioenergetics and its frequent appearance in research designs alongside MOTS-c and SS-31. Many suppliers serving the mitochondrial research domain carry both peptide and non-peptide compounds in this category.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003cem\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg\/10mg\/600mg (one vial)","offer_id":46211113713801,"sku":null,"price":164.99,"currency_code":"CAD","in_stock":false},{"title":"6 x 10mg\/10mg\/600mg","offer_id":46211113746569,"sku":null,"price":899.99,"currency_code":"CAD","in_stock":false},{"title":"10 x 10mg\/10mg\/600mg (one box)","offer_id":46211113779337,"sku":null,"price":1369.99,"currency_code":"CAD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/mots-c-ss-31-nad_-mito-stack-peptide-canada_standardized_7a60a455-0cdf-4180-aa0a-b728c3f5e20c.png?v=1778371936"}],"url":"https:\/\/emeraldpeptides.ca\/collections\/best-peptides-canada.oembed","provider":"Emerald Peptides","version":"1.0","type":"link"}